CN111228252B - 丙炔胺类衍生物在制药中的应用 - Google Patents
丙炔胺类衍生物在制药中的应用 Download PDFInfo
- Publication number
- CN111228252B CN111228252B CN202010071179.5A CN202010071179A CN111228252B CN 111228252 B CN111228252 B CN 111228252B CN 202010071179 A CN202010071179 A CN 202010071179A CN 111228252 B CN111228252 B CN 111228252B
- Authority
- CN
- China
- Prior art keywords
- nmr
- cdcl
- compound
- mao
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- RTWCHRMHGXBETA-UHFFFAOYSA-N prop-1-yn-1-amine Chemical class CC#CN RTWCHRMHGXBETA-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 67
- 239000003814 drug Substances 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 208000024827 Alzheimer disease Diseases 0.000 claims description 11
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 3
- 102000010909 Monoamine Oxidase Human genes 0.000 abstract description 33
- 108010062431 Monoamine oxidase Proteins 0.000 abstract description 33
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical class NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 abstract description 19
- 229940079593 drug Drugs 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 8
- 239000003112 inhibitor Substances 0.000 abstract description 7
- 150000001335 aliphatic alkanes Chemical class 0.000 abstract description 4
- 229910052799 carbon Inorganic materials 0.000 abstract description 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 4
- 229910052760 oxygen Inorganic materials 0.000 abstract description 4
- 229910052717 sulfur Inorganic materials 0.000 abstract description 4
- 230000004770 neurodegeneration Effects 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 abstract description 3
- 208000015122 neurodegenerative disease Diseases 0.000 abstract description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 37
- 238000005481 NMR spectroscopy Methods 0.000 description 37
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 239000003960 organic solvent Substances 0.000 description 15
- 239000002253 acid Substances 0.000 description 14
- 239000011230 binding agent Substances 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 239000000543 intermediate Substances 0.000 description 14
- 238000000034 method Methods 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 10
- 230000008499 blood brain barrier function Effects 0.000 description 9
- 210000001218 blood-brain barrier Anatomy 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000003208 petroleum Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000004220 aggregation Methods 0.000 description 6
- 230000035699 permeability Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 208000010412 Glaucoma Diseases 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 208000013677 cerebrovascular dementia Diseases 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 206010028417 myasthenia gravis Diseases 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- HQFYIDOMCULPIW-UHFFFAOYSA-N n-methylprop-2-yn-1-amine Chemical compound CNCC#C HQFYIDOMCULPIW-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 229960000245 rasagiline Drugs 0.000 description 4
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- PKYCWFICOKSIHZ-UHFFFAOYSA-N 1-(3,7-dihydroxyphenoxazin-10-yl)ethanone Chemical compound OC1=CC=C2N(C(=O)C)C3=CC=C(O)C=C3OC2=C1 PKYCWFICOKSIHZ-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000000823 artificial membrane Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 3
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 2
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 2
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 2
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 2
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 2
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 2
- 229940086616 Monoamine oxidase B inhibitor Drugs 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 2
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 238000013149 parallel artificial membrane permeability assay Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 101000694718 Homo sapiens Amine oxidase [flavin-containing] A Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- NYMGNSNKLVNMIA-UHFFFAOYSA-N Iproniazid Chemical compound CC(C)NNC(=O)C1=CC=NC=C1 NYMGNSNKLVNMIA-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000006933 amyloid-beta aggregation Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000013039 cover film Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940052764 dopaminergic anti-parkinson drug mao b inhibitors Drugs 0.000 description 1
- 238000010799 enzyme reaction rate Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 102000000154 human monoamine oxidase A Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940070023 iproniazide Drugs 0.000 description 1
- 229950005862 lazabemide Drugs 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- JZXRLKWWVNUZRB-UHFFFAOYSA-N n-(2-aminoethyl)-5-chloropyridine-2-carboxamide Chemical compound NCCNC(=O)C1=CC=C(Cl)C=N1 JZXRLKWWVNUZRB-UHFFFAOYSA-N 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 229960003732 tyramine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/16—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring not being further substituted
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/83—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一类丙炔胺类衍生物在制药中的应用。申请人的试验表明，该类衍生物能选择性的抑制MAO‑B且活性显著，可用于制备MAO‑B抑制剂以及预防和/或治疗AD病等相关神经退行性疾病的药物。其中所述的丙炔胺类衍生物为具有下述式(I)所示结构的化合物或其药学上可接受的盐：
其中：n＝1～10；R表示下述式(A)～(E)所示结构中的任意一种：
在式(A)～(E)所示结构中，R1表示任意位置取代的H、F、Cl、Br、OH、OCH3、NO2、CH3、CF3、COCH3、COOCH3或CH2OH，或者是C2～C5直连或支链烷烃；X表示O、N、S或C。
Description
技术领域
本发明涉及医药技术领域，具体涉及丙炔胺类衍生物在制药中的应用。
背景技术
阿尔茨海默病(Alzheimer’s disease,AD)又称老年痴呆，是一种临床表现为认知和记忆功能不断恶化，日常生活能力进行性衰退并伴有各种神经精神症状和行为障碍的神经退行性疾病。目前治疗AD的药物有限，开发新型有效的AD治疗药物具有重要的意义。
单胺氧化酶(Monoamine oxidase,MAO)是一种位于线粒体外膜的黄素蛋白酶。它能催化氧化生物体内的各种胺类物质最终生成相应的醛和过氧化氢。根据对底物和抑制剂的敏感性，单胺氧化酶分为A和B两种亚型。已有的研究发现，MAO-B在AD患者大脑中显著增加，增高的MAO-B水平，增加了对脑内胺类神经递质的催化，生成大量过氧化氢，从而诱导氧化应激(Oxidative stress,OS)导致一系列AD相关病理事件的发生。除此之外，MAO-B还可以通过多种途径影响AD的病理过程：(1)MAO-B直接调控γ-分泌酶和β-分泌酶的生成进而促进淀粉样前体蛋白(Amyloid precursor protein,APP)的分解生成Aβ；(2)激活的MAO-B可以破坏胆碱能神经元造成胆碱能神经系统紊乱；(3)MAO-B能促进tau蛋白的异常磷酸化，促进神经元纤维缠结的形成(NFTs)；(4)MAO-B水解过量的胺类神经递质导致脑内其它神经递质的再分布。
临床上，一些MAO-B选择性抑制剂的应用在一定程度上能缓解AD患者的认知症状。如司来吉兰(Selegiline)可以提高中重度AD患者的认知能力，拉扎贝胺(Lazabemide)则在II期临床试验中对比安慰剂组可以降低20-40％的认知下降。因此，开发新型有效的选择性MAO-B抑制剂成为AD治疗的有效途径。但目前尚未发现有丙炔胺类衍生物及其合成方法以及将其应用于治疗AD方面的相关报道。
发明内容
本发明要解决的技术问题是提供一系列结构新颖的丙炔胺类衍生物在制药中的应用。
本发明涉及丙炔胺类衍生物在制药中的多种应用，其中所述的丙炔胺类衍生物为具有下述式(I)所示结构的化合物或其药学上可接受的盐：
其中：
n＝1～10；
R表示下述式(A)～(E)所示结构中的任意一种：
上述式(A)～(E)所示结构中，R1表示任意位置取代的H、F、Cl、Br、OH、OCH3、NO2、CH3、CF3、COCH3、COOCH3或CH2OH，或者是C2～C5直连或支链烷烃；X表示O、N、S或C。
为方便描述，在本申请说明书的以下内容中出现的“丙炔胺类衍生物”可以理解为上述对R、R1和n进行限定的式(I)所示结构的化合物的简称。
本发明的第一个目的在于提供丙炔胺类衍生物或其药学上可接受的盐在制备单胺氧化酶B抑制剂中的应用。
本发明的第二个目的在于提供丙炔胺类衍生物或其药学上可接受的盐在制备治疗阿尔茨海默病、脑血管痴呆、青光眼或重症肌无力的药物中的应用。
本发明的第三个目的在于提供丙炔胺类衍生物或其药学上可接受的盐在制备改善阿尔茨海默病、脑血管痴呆、青光眼或重症肌无力的保健品中的应用。
本发明的第四个目的在于提供一种单胺氧化酶B抑制剂，它含有治疗上有效剂量的丙炔胺类衍生物或其药学上可接受的盐，以及药学上可接受的辅料。
本发明的第五个目的在于提供一种治疗阿尔茨海默病、脑血管痴呆、青光眼或重症肌无力的药物，它含有治疗上有效剂量的丙炔胺类衍生物或其药学上可接受的盐，以及药学上可接受的辅料。
本发明的第六个目的在于提供一种改善阿尔茨海默病、脑血管痴呆、青光眼或重症肌无力的保健品，它含有丙炔胺类衍生物或其药学上可接受的盐，以及药学上可接受的辅料。
上述提及的单胺氧化酶B抑制剂、治疗阿尔茨海默病、脑血管痴呆、青光眼或重症肌无力的药物或保健品的剂型可以是药学上可接受的任意剂型，具体可以是颗粒剂、片剂、丸剂、胶囊或注射剂等常规剂型。
本发明中涉及的丙炔胺类衍生物优选为包括下述式I-1～I-20所示结构中的至少一种化合物：
本发明中涉及的丙炔胺类衍生物的药学上可接受的盐，具体可以是上述式(I)所示结构化合物的盐酸盐、马来酸盐、枸橼酸盐、硫酸盐、马来酸盐、三氟乙酸盐、柠檬酸盐、酒石酸盐、苯磺酸盐、乙酸盐、丙酸盐、酒石酸盐、乙磺酸盐、苯甲酸盐或对甲苯磺酸盐等。式(I)所示化合物药学上可接受的盐具有与式(I)所示化合物同样或更好的药效活性。
本发明中涉及的丙炔胺类衍生物可以自行设计路线进行合成，优选按下述方法进行合成：
1)取下述式(A)～(E)所示结构中的任意一种化合物和过量的二溴烷烃置于有机溶剂中，加入缚酸剂，于加热或不加热条件下反应，所得反应物料固液分离，收集滤液，经纯化后得到相应的中间体；
上述式(A)～(E)所示结构中，R1表示任意位置取代的H、F、Cl、Br、OH、OCH3、NO2、CH3、CF3、COCH3、COOCH3或CH2OH，或者是C1～C5直连或支链烷烃；X表示O、N、S或C；
所述的二溴烷烃为Br(CH2)nBr，n＝1～10；
2)取中间体和N-甲基炔丙基胺置于有机溶剂中，加入缚酸剂，于加热或不加热条件下反应，得到相应的目标化合物粗品。
上述合成方法的步骤1)和2)中，所述的有机溶剂具体可以是选自丙酮、DMF、乙腈、四氢呋喃和二甲亚砜中的一种或两种以上的组合；所述有机溶剂的用量可以根据需要进行确定，通常情况下，以1mmol的式(A)～(E)所示结构中的一种化合物或中间体为基准计算，有机溶剂的用量一般为2-10mL。所述的缚酸剂为现有技术中的常规选择，具体可以是选自碳酸钾、碳酸铯、碳酸氢钠、碳酸钠、氢氧化钠、氢氧化钾、吡啶和三乙胺中的一种或两种以上的组合；缚酸剂的加入量为使得体系在碱性条件下反应，优选控制体系的pH＝8-12。
上述合成方法的步骤1)和2)中，当反应在不加热的条件下进行时，所得产物的产率较低，因此，优选反应在加热条件下进行，进一步优选反应在50℃至有机溶剂的沸点温度范围内进行，更优选反应在60～80℃条件下进行。反应是否完全可采用薄层层析跟踪检测。
上述合成方法的步骤1)中，所述的二溴烷烃为中n的取值优选为3～8；所述二溴烷烃的用量必须是过量的，其用量优选为式(A)～(E)所示结构中的任意一种化合物物质的量的10～30倍。该步骤1)中，收集的滤液可以采用硅胶柱层析或高效液相色谱纯化以得到相应的中间体。当收集的滤液经硅胶柱纯化时，采用由石油醚和乙酸乙酯组成的混合溶剂作为洗脱剂，其中石油醚可以用环己烷、正己烷、正戊烷、异戊烷、环戊烷或异辛烷代替，乙酸乙酯可以用丙酮、氯仿、二氧六环、四氢呋喃或二氯甲烷代替。在混合溶剂的组成中，石油醚(环己烷等)和乙酸乙酯(丙酮等)的体积比优选为5～30：1，更优选为5～20：1，最优选为10：1。
上述合成方法的步骤2)中，中间体和N-甲基炔丙基胺的摩尔比为化学计量比，在实际的操作过程中，N-甲基炔丙基胺可稍微过量。
由上述方法制得的是式(I)所示化合物的粗品，可采用现有常规的纯化方法对其进行纯化以提高式(I)所示化合物的纯度。通常是将制得的目标化合物粗品上硅胶柱或高效液相色谱层析以得到纯化后的目标化合物。当将目标化合物粗品上硅胶柱层析进行纯化时，采用由石油醚和乙酸乙酯组成的混合溶剂作为洗脱剂，其中石油醚可以用环己烷、正己烷、正戊烷、异戊烷、环戊烷或异辛烷代替，乙酸乙酯可以用丙酮、氯仿、二氧六环、四氢呋喃或二氯甲烷代替。在混合溶剂的组成中，石油醚(环己烷等)和乙酸乙酯(丙酮等)的体积比优选为1～20：1，更优选为1～10：1，最优选为4：1。
与现有技术相比，本发明提供了一系列结构新颖的丙炔胺类衍生物及其药学上可接受的盐在制药中的应用，申请人的实验结果表明，本发明所述的丙炔胺类衍生物能够选择性的抑制MAO-B，部分衍生物更是表现出极为显著的抑制活性，可用于制备MAO-B抑制剂以及预防或/和治疗阿尔茨海默病等相关神经退行性疾病的药物。
附图说明
图1为本发明所述目标化合物血脑屏障通透性相关参数曲线。
图2为本发明所述目标化合物I-10在不浓度下神经细胞SH-SY5Y的生存率柱状图。
具体实施方式
下面结合具体实施例对本发明作进一步的详述，以更好地理解本发明的内容，但本发明并不限于以下实施例。
本发明所述目标化合物的合成路线如下：
其中，n＝1～10；
R表示下述式(A)～(E)所示结构中的任意一种：
上述式(A)～(E)所示结构中，R1表示任意位置取代的H、F、Cl、Br、OH、OCH3、NO2、CH3、CF3、COCH3、COOCH3或CH2OH，或者是C2～C5直连或支链烷烃；X表示O、N、S或C。
实施例1：中间体的制备
称取式(A)～(E)所示结构中的任意一种(6mmol)溶解于10mL有机溶剂(中间体A1～A4采用的有机溶剂为DMF，其余中间体采用的有机溶剂均为丙酮)中，溶解完全后，加入缚酸剂(中间体A1～A4及B1～B8采用的缚酸剂为碳酸钾，中间体C1～C4采用的缚酸剂为碳酸铯，中间体D1及E1～E3采用的缚酸剂为碳酸钠)(7.2mol,1.2当量)室温下搅拌1分钟，然后加入过量的二溴烷烃(120mmol，20当量)，于70℃下搅拌反应，TLC跟踪检测直至反应完全，反应结束，抽滤，滤液减压浓缩，残余物经硅胶柱层析分离(石油醚：乙酸乙酯＝10：1，体积比)，得到相应的中间体，其具体结构如表1所示。表1中间体的具体结构
实施例2：目标化合物I-1～I-20的制备
称取相应中间体(2mmol)溶解于10mL有机溶剂(目标化合物I-1～I-8采用的有机溶剂为乙腈，目标化合物I-9～I-15采用的有机溶剂为丙酮，目标化合物I-16～I-18采用的有机溶剂为四氢呋喃，目标化合物I-19采用的有机溶剂为DMF，目标化合物I-20采用的有机溶剂为二甲基亚砜)中，溶解完全后，加入缚酸剂(目标化合物I-1～I-15采用的缚酸剂为三乙胺，目标化合物I-16采用的缚酸剂为碳酸钠，目标化合物I-17采用的缚酸剂为吡啶，目标化合物I-18～I-20采用的缚酸剂为碳酸氢钠)(4mmol，2当量)和N-甲基炔丙基胺(2.2mmol)，加入完毕后，加热条件下回流反应(目标化合物I-1～I-5的反应温度为70℃，时间为8h；目标化合物I-6～I-15的反应温度为80℃，时间为6h；目标化合物I-16～I-19的反应温度为50℃，时间为10h；目标化合物I-20在常温条件下反应，时间为12h)，所得反应液减压浓缩，残余物经硅胶柱层析分离纯化(石油醚：乙酸乙酯＝4：1，体积比)，得相应的目标化合物，其结构如表2所示。
表2目标化合物I-1～I-20的具体结构
不同的目标产物及其表征如下：
I-1：产率83％,淡黄色油状物.1H NMR(500MHz,CDCl3)δ7.68–7.63(m,1H),6.87(d,J＝5.4Hz,2H),4.04(t,J＝6.3Hz,2H),3.36(d,J＝2.2Hz,2H),3.12–3.02(m,2H),2.69–2.61(m,2H),2.54–2.47(m,2H),2.32(s,3H),2.22(t,J＝2.2Hz,1H),1.89–1.80(m,2H),1.72–1.61(m,2H).13C NMR(126MHz,CDCl3)δ205.45,164.83,158.27,130.35,125.42,115.74,110.36,78.38,73.41,68.17,55.18,45.59,41.75,36.53,26.95,25.97,24.03.HRMS:calcd for C17H21NO2[M+H]+272.1645,found 272.1658.
I-2：产率87％,淡黄色油状物.1H NMR(500MHz,CDCl3)δ7.68–7.62(m,1H),6.89–6.83(m,2H),4.01(t,J＝6.4Hz,2H),3.34(d,J＝2.3Hz,2H),3.09–3.02(m,2H),2.68–2.60(m,2H),2.47–2.43(m,2H),2.31(s,3H),2.22(t,J＝2.3Hz,1H),1.88–1.77(m,2H),1.59–1.45(m,4H).13C NMR(126MHz,CDCl3)δ205.45,164.87,158.28,130.30,125.41,115.73,110.31,78.40,73.38,68.33,55.53,45.58,41.82,36.52,29.04,27.29,25.96,23.92.HRMS:calcd for C18H23NO2[M+H]+286.1802,found 286.1813.
I-3：产率78％,淡黄色固体.1H NMR(500MHz,CDCl3)δ7.68–7.64(m,1H),6.87(d,J＝4.9Hz,2H),4.01(t,J＝6.5Hz,2H),3.34(d,J＝2.2Hz,2H),3.10–3.03(m,2H),2.69–2.60(m,2H),2.48–2.38(m,2H),2.30(s,3H),2.21(t,J＝2.2Hz,1H),1.87–1.76(m,2H),1.49(dq,J＝14.5,7.2Hz,4H),1.39(dd,J＝14.3,7.5Hz,2H).13C NMR(126MHz,CDCl3)δ205.43,164.92,158.27,130.30,125.41,115.74,110.34,78.48,73.31,68.41,55.64,45.57,41.84,36.52,29.12,27.53,27.19,26.02,25.96.HRMS:calcd for C19H25NO2[M+H]+300.1958,found 300.1961.
I-4：产率86％,黄色油状物.1H NMR(500MHz,CDCl3)δ7.55(d,J＝8.6Hz,1H),6.63(dd,J＝8.6,1.7Hz,1H),6.51(d,J＝1.5Hz,1H),4.61(s,2H),4.01(t,J＝6.4Hz,2H),3.41(s,2H),2.55–2.47(m,2H),2.37(s,3H),2.27(s,1H),1.86–1.77(m,2H),1.55(dd,J＝15.0,7.5Hz,2H),1.51–1.46(m,2H),1.43–1.36(m,2H).13C NMR(126MHz,CDCl3)δ196.72,175.69,166.88,124.18,113.28,111.20,95.88,74.67,73.06,67.77,54.53,44.44,40.66,27.96,26.20,26.12,24.97.HRMS:calcd for C18H23NO3[M+H]+302.1751,found 302.1764.
I-5：产率91％,淡黄色油状物.1H NMR(500MHz,CDCl3)δ7.96(d,J＝8.7Hz,1H),6.78(dd,J＝8.7,1.9Hz,1H),6.67(s,1H),4.01(t,J＝6.3Hz,2H),3.34(d,J＝1.8Hz,2H),2.88(t,J＝6.0Hz,2H),2.60–2.54(m,2H),2.47(t,J＝7.3Hz,2H),2.30(s,3H),2.21(s,1H),2.12–2.04(m,2H),1.86–1.77(m,2H),1.68–1.57(m,2H).13C NMR(126MHz,CDCl3)δ197.30,163.10,147.00,129.66,126.22,113.50,113.18,78.46,77.16,73.30,67.87,55.16,45.57,41.73,38.96,30.22,26.95,24.02,23.45.HRMS:calcd for C18H23NO2[M+H]+286.1801,found 286.1815.
I-6：产率76％,淡黄色油状物.1H NMR(500MHz,CDCl3)δ7.96(d,J＝8.7Hz,1H),6.77(dd,J＝8.7,2.1Hz,1H),6.66(d,J＝1.4Hz,1H),3.98(t,J＝6.4Hz,2H),3.32(d,J＝2.1Hz,2H),2.88(t,J＝6.0Hz,2H),2.59–2.54(m,2H),2.42(t,J＝7.1Hz,2H),2.29(s,3H),2.21(t,J＝2.0Hz,1H),2.11–2.03(m,2H),1.85–1.75(m,2H),1.56–1.42(m,4H).13C NMR(126MHz,CDCl3)δ197.31,163.14,147.00,129.65,126.18,113.48,113.14,78.47,73.27,68.02,55.50,45.55,41.79,38.94,30.20,29.03,27.28,23.88,23.43.HRMS:calcd forC19H25NO2[M+H]+300.1958,found 300.1970.
I-7：产率74％,淡黄色油状物.1H NMR(500MHz,CDCl3)δ7.97(d,J＝8.7Hz,1H),6.78(dd,J＝8.7,2.4Hz,1H),6.67(d,J＝2.2Hz,1H),3.98(t,J＝6.5Hz,2H),3.34(d,J＝2.3Hz,2H),2.89(t,J＝6.1Hz,2H),2.58(t,J＝6.5Hz,2H),2.42(t,J＝6.5Hz,2H),2.30(s,3H),2.21(t,J＝2.3Hz,1H),2.14–2.04(m,2H),1.84–1.74(m,2H),1.48(m,4H),1.38(m,2H).13C NMR(126MHz,CDCl3)δ197.35,163.21,147.02,129.68,126.19,113.50,113.19,78.45,73.31,68.11,55.63,45.54,41.81,38.98,30.24,29.13,27.50,27.18,26.00,23.47.HRMS:calcd for C20H27NO2[M+H]+314.2114,found 314.2127.
I-8：产率81％,黄色固体.1H NMR(500MHz,CDCl3)δ7.81(d,J＝8.8Hz,1H),6.56(dd,J＝8.8,2.2Hz,1H),6.39(d,J＝2.2Hz,1H),4.49(t,J＝6.4Hz,2H),4.03(t,J＝6.3Hz,2H),3.36(d,J＝2.2Hz,2H),2.73(t,J＝6.4Hz,2H),2.60(t,J＝7.1Hz,2H),2.33(s,3H),2.23(t,J＝2.3Hz,1H),1.95(p,J＝6.6Hz,2H).13C NMR(126MHz,CDCl3)δ190.65,165.49,163.87,128.93,115.29,110.33,101.37,78.27,73.52,67.46,66.47,52.13,45.75,41.76,37.53,27.14.HRMS:calcd for C16H19NO3[M+H]+274.1438,found 274.1438.
I-9：产率71％,淡黄色油状物.1H NMR(500MHz,CDCl3)δ7.82(d,J＝8.8Hz,1H),6.56(dd,J＝8.8,2.4Hz,1H),6.38(d,J＝2.3Hz,1H),4.50(t,J＝6.3Hz,2H),4.00(t,J＝6.3Hz,2H),3.37(d,J＝2.3Hz,2H),2.74(t,J＝5.0Hz,2H),2.50(t,J＝5.0Hz,2H),2.33(s,3H),2.23(t,J＝2.4Hz,1H),1.87–1.77(m,2H),1.64(m,2H).13C NMR(126MHz,CDCl3)δ190.77(s),165.63(s),163.78(s),128.95(s),115.29(s),110.31(s),101.28(s),78.01(s)73.69(s),68.09(s),67.43(s),55.06(s),45.73(s),42.00(s),37.29(s),27.07(s),23.98(s).HRMS:calcd for C17H21NO3[M+H]+288.1594,found 288.1568.
I-10：产率89％,黄色油状物.1H NMR(500MHz,CDCl3)δ7.82(d,J＝8.8Hz,1H),6.55(dd,J＝8.8,2.4Hz,1H),6.38(d,J＝2.3Hz,1H),4.50(t,J＝6.4Hz,2H),3.98(t,J＝6.4Hz,2H),3.37(d,J＝2.3Hz,2H),2.74(t,J＝5.0Hz 2H),2.47(t,J＝5.0Hz,2H),2.33(s,3H),2.24(t,J＝2.4Hz,1H),1.81(q,J＝6.6Hz,2H),1.60–1.52(m,2H),1.48(m,2H).13C NMR(126MHz,CDCl3)δ190.76,165.61,163.90,128.97,115.30,110.32,101.29,78.27,73.69,68.35,67.49,55.53,45.59,41.82,37.57,28.98,27.38,23.92.HRMS:calcd for C18H23NO3[M+H]+302.1751,found 302.1745.
I-11：产率73％,淡黄色油状物.1H NMR(500MHz,CDCl3)δ7.82(d,J＝8.8Hz,1H),6.56(dd,J＝8.8,2.3Hz,1H),6.38(d,J＝2.3Hz,1H),4.58–4.45(m,2H),3.97(t,J＝6.4Hz,2H),3.46(s,2H),2.79–2.70(m,2H),2.62–2.51(m,2H),2.42(s,3H),2.31(s,1H),1.86–1.73(m,2H),1.58(dt,J＝15.0,7.6Hz,2H),1.52–1.45(m,2H),1.40(dd,J＝15.1,8.1Hz,2H).13C NMR(126MHz,CDCl3)δ190.69,165.63,163.92,128.98,115.26,110.39,101.31,68.37,67.50,55.47,45.34,41.52,37.57,29.01,27.07,25.94,26.93.HRMS:calcd forC19H25NO3[M+H]+316.1907,found 316.1913.
I-12：产率89％,淡黄色油状物.1H NMR(500MHz,CDCl3)δ7.82(d,J＝8.8Hz,1H),6.56(dd,J＝8.8,2.3Hz,1H),6.38(d,J＝2.3Hz,1H),4.50(t,J＝6.4Hz,2H),3.97(t,J＝6.5Hz,2H),3.39(d,J＝2.1Hz,2H),2.74(t,J＝5.0Hz,2H),2.46(t,J＝5.0Hz,2H),2.35(s,3H),2.25(t,J＝2.3Hz,1H),1.77(m,2H),1.55–1.40(m,4H),1.33(br,6H).13C NMR(126MHz,CDCl3)δ190.68,165.69,163.91,128.95,115.21,110.41,101.29,77.90,73.84,68.52,67.48,55.73,45.47,41.71,37.57,29.50,29.34,29.07,27.37,26.01.HRMS:calcd forC21H29NO3[M+H]+344.2220,found 344.2221.
I-13：产率81％,淡黄色油状物.1H NMR(500MHz,DMSO)δ7.91(d,J＝8.8Hz,2H),7.02(d,J＝8.8Hz,2H),4.06(t,J＝6.5Hz,2H),3.29(s,3H),3.10(s,1H),2.39(t,J＝7.1Hz,2H),2.19(s,3H),1.78–1.68(m,2H),1.53(dt,J＝14.6,7.3Hz,2H),1.34(s,2H).13CNMR(126MHz,DMSO)δ196.32,162.55,130.51,129.75,114.28,75.77,67.70,54.45,44.89,41.18,29.80,26.42,26.31,23.24.HRMS:calcd for C16H21NO2[M+H]+260.1645,found260.1651.
I-14：产率74％,淡黄色油状物.1H NMR(500MHz,DMSO)δ8.00–7.80(m,2H),7.09–6.93(m,2H),4.04(t,J＝6.5Hz,2H),3.27(s,3H),3.09(s,1H),2.32(t,J＝7.1Hz,2H),2.17(s,3H),1.77–1.68(m,2H),1.43–1.36(m,4H),1.35–1.27(m,4H).13C NMR(126MHz,DMSO)δ196.31,162.58,130.50,129.74,114.26,75.68,67.85,54.87,44.90,41.29,28.53,26.79,26.55,26.42,25.36.HRMS:calcd for C18H25NO2[M+H]+288.1958,found 288.1966.
I-15：产率84％,淡黄色油状物.1H NMR(500MHz,DMSO)δ7.15(t,J＝8.2Hz,1H),6.50(t,J＝2.5Hz,1H),6.48(t,J＝2.4Hz,1H),6.46(t,J＝2.3Hz,1H),3.92(t,J＝6.5Hz,2H),3.72(s,3H),3.10(s,1H),2.35(s,2H),2.18(s,3H),1.69(dd,J＝12.8,5.9Hz,2H),1.46–1.38(m,4H),1.35(d,J＝2.6Hz,2H).13C NMR(126MHz,DMSO)δ160.94,160.39,130.37,107.03,106.61,101.07,67.81,55.51,55.28,45.33,30.24,29.00,23.83.HRMS:calcd forC16H23NO2[M+H]+262.1801,found 266.1809.
I-16：产率75％,淡黄色固体.1H NMR(500MHz,CDCl3)δ7.54(dd,J＝8.3,2.0Hz,1H),7.50(d,J＝2.0Hz,1H),6.87(d,J＝8.4Hz,1H),4.10(t,J＝6.6Hz,2H),3.90(s,3H),3.35(d,J＝2.4Hz,2H),2.55(s,3H),2.51–2.45(m,2H),2.31(s,3H),2.21(t,J＝2.4Hz,1H),1.89(dd,J＝14.9,6.8Hz,2H),1.65(dt,J＝15.0,7.5Hz,2H).13C NMR(126MHz,CDCl3)δ196.71,152.70,149.08,130.14,123.09,111.01,110.25,78.27,72.91,68.39,55.86,54.81,45.35,41.50,26.60,25.99,23.59.HRMS:calcd for C17H23NO3[M+H]+290.1751,found 290.1749.
I-17：产率79％,黄色固体.1H NMR(500MHz,CDCl3)δ7.54(dd,J＝8.3,2.0Hz,1H),7.50(d,J＝2.0Hz,1H),6.87(d,J＝8.4Hz,1H),4.10(t,J＝6.6Hz,2H),3.90(s,3H),3.35(d,J＝2.4Hz,2H),2.55(s,3H),2.51–2.45(m,2H),2.31(s,3H),2.21(t,J＝2.4Hz,1H),1.89(dd,J＝14.9,6.8Hz,2H),1.65(dt,J＝15.0,7.5Hz,2H).13C NMR(126MHz,CDCl3)δ196.98,152.98,149.29,130.28,123.49,111.09,110.55,78.51,73.31,68.97,56.13,55.54,45.61,41.84,28.96,27.30,26.34,23.88.HRMS:calcd for C18H25NO3[M+H]+304.1907,found 304.1908.
I-18：产率79％,红色固体.1H NMR(500MHz,CDCl3)δ10.26(s,1H),7.78(d,J＝8.7Hz,1H),6.52(dd,J＝8.7,1.9Hz,1H),6.43(d,J＝2.0Hz,1H),4.04(t,J＝6.3Hz,2H),3.88(s,3H),3.36(s,2H),2.53–2.47(m,2H),2.32(s,3H),2.22(t,J＝2.3Hz,1H),1.88–1.79(m,2H),1.70–1.60(m,2H).13C NMR(126MHz,CDCl3)δ188.48,165.80,163.71,130.85,119.01,106.28,98.45,78.38,73.42,68.17,55.71,55.16,45.60,41.77,26.96,24.02.HRMS:calcd for C16H21NO3[M+H]+276.1594,found 276.1601.
I-19：产率82％,黄色固体.1H NMR(500MHz,CDCl3)δ10.24(s,1H),7.76(d,J＝8.7Hz,1H),6.49(dd,J＝8.7,1.8Hz,1H),6.41(d,J＝1.9Hz,1H),4.00(t,J＝6.4Hz,2H),3.87(s,3H),3.33(d,J＝2.2Hz,2H),2.43(t,J＝7.1Hz,2H),2.37(s,1H),2.29(s,3H),2.21(t,J＝2.2Hz,1H),1.87–1.76(m,2H),1.50(t,J＝11.4Hz,4H).13C NMR(126MHz,CDCl3)δ188.44,165.82,163.68,130.79,118.92,106.24,98.38,78.48,73.29,68.33,55.66,55.50,45.56,41.81,29.02,27.29,23.89.HRMS:calcd for C17H23NO3[M+H]+290.1751,found 290.1764.
I-20：产率73％,黄色粉末.1H NMR(500MHz,CDCl3)δ10.26(s,1H),7.77(d,J＝8.7Hz,1H),6.51(dd,J＝8.7,1.5Hz,1H),6.42(d,J＝1.8Hz,1H),4.00(t,J＝6.5Hz,2H),3.88(s,3H),3.34(d,J＝2.1Hz,2H),2.48–2.38(m,2H),2.30(s,3H),2.21(t,J＝2.2Hz,1H),1.85–1.74(m,2H),1.55–1.44(m,4H),1.39(dd,J＝14.5,7.6Hz,2H).13C NMR(126MHz,CDCl3)δ188.44,165.87,163.70,130.82,118.94,106.26,98.41,78.47,73.31,68.41,55.64,45.57,41.83,29.14,27.53,27.19,26.01.HRMS:calcd for C18H25NO3[M+H]+304.1907,found 304.1921.
实验例1：对按本发明所述目标化合物对单胺氧化酶A和B的抑制活性测定
采用Amplex red荧光法测定单胺氧化酶抑制活性。重组人单胺氧化酶A(E.C.1.4.3.4)和单胺氧化酶B(E.C.1.4.3.4)用作活性测试用酶源。异丙烟肼(Iproniazid)和雷沙吉兰(Rasagiline)用作阳性对照。
实验方法：将所测试化合物溶解于DMSO中，用缓冲液(0.05M KH2PO4/K2HPO4buffer,pH＝7.4)稀释到所需浓度。在96孔黑色酶标板中，依次加入20μL待测化合物和80μL单胺氧化酶A，轻拍使其混匀后，于37℃下避光孵育15min。孵育结束后，依次加入终浓度为200μM的Amplex Red试剂,2U/mL的辣根过氧化物酶和2mM的对酪胺。加入完成后，立即转入酶标仪中，于37℃下，测定其在30min内的荧光强度变化(excitation,545nm；emission,590nm)。在孵育过程中，MAO-A可催化底物酪胺氧化并释放过氧化氢，释放的过氧化氢作用于Amplex red并将其转化为具有荧光的物质试卤灵。为了避免化合物对辣根过氧化物酶的干扰，以3％的过氧化氢为代替酶进行平行对照试验。
测定结束后，根据其荧光强度变化并按照以下公式计算抑制率(％)：抑制率(％)＝{1-[(IF实验组-IF平行对照组)/(IF空白组-IF平行对照组)]}×100％。实验重复三次取平均值，利用GraphPad软件计算化合物对单胺氧化酶A的半数抑制浓度(IC50)；单胺氧化酶B的抑制活性测定方法同MAO-A抑制活性相同只是将所用的单胺氧化酶A替换为单胺氧化酶B，同时调整酶反应速率相同。测定结果如表3所示。
表3各目标化合物对MAO-A和MAO-B的抑制活性结果
b表示化合物在100μM浓度下的抑制率。
由表3可知，本发明所述各目标化合物都表现出了对MAO-B显著的抑制活性，而对MAO-A的抑制活性较弱，显示出本发明所述目标化合物对MAO-B良好的选择性。其中，化合物I-10为本系列最优化合物其对MAO-A的抑制率在100μM下为6.04％，而对MAO-B的抑制IC50值达4nM，远高于阳性对照药物雷沙吉兰，是一种有效选择性MAO-B抑制剂。
实验例2：本发明所述目标化合物的血脑屏障透过性
采用PAMPA-BBB人工膜法测定。采用猪脑磷脂构建体外透膜模型。通过测定9个具有不同血脑屏障透过性的药物，建立当前血脑屏障透过性曲线。
具体方法：PAMPA模型实验在96孔滤板中进行，配制浓度为2％的牛脑磷脂/十二烷(V/V)的溶液，超声溶解直至混合均匀。吸取该溶液5μL加在PAMPA供给板各孔中的亲脂性滤膜上，对照孔加入5μL的十二烷溶液。在接收板各孔中加入300μL的缓冲液(PBS/EtOH＝70:30，V/V，pH＝7.4)，在供给板各孔中加入150μL待测药液(每个药物在人工膜及对照膜均重复3次)，整个加药过程在10min内完成。将供给板放在接收板上，盖上盖子，将整个96孔滤板装置放置恒温培养箱中(25℃)孵育16h，孵育结束后，收集供体板和接收板的溶液，测定浓度，依照下述公式计算透过率Pe：Pe＝{-VdVa/[(Vd+Va)At]}ln(1-drugacceptor/drugequilibrium)，其中Vd为供体孔体积(mL)，Va为接收孔体积(mL)，A为滤膜面积(cm2)，t为渗透时间(s)，drugacceptor为t时间接收板溶液浓度，drugequilibrium为理论平衡吸收浓度。通过将已知标准药物的文献Pe值和实测Pe值比较建立的标准曲线，求出此次血脑屏障透过Pe值范围，判定化合物的透过性。结果如下述表4所示。
表4 PAMPA-BBB人工膜法测定的9个对比药物的渗透系数Pe(×106cm/s).
a数据来源于文献Eur.J.Med.Chem.2003,38:223–232。
b三次独立实验平均值，表示为平均值±SD，溶剂配比为PBS:EtOH＝70:30。
对比实验测定的9个药物Pe值(表4)和文献报道数值作线性回归(如图1所示)，得到的一个良好的线性关系公式：Pe(exp.)＝0.9707Pe(bibl.)-0.1043(R2＝0.9573)。根据文献报道的血脑屏障透过数值结合当前计算公式，得到当Pe(×106cm/s)>3.78时化合物可以很好的透过血脑屏障。如表5所示，本发明所述目标化合物Pe值均大于3.78，说明这些化合物均能很好的透过血脑屏障。
表5目标化合物在PAMPA-BBB测定中的Pe(×106cm/s)值。
a三次独立实验平均值，表示为平均值±SD，溶剂配比为PBS:EtOH＝70:30，体积比。
bCNS+代表化合物可以透过血脑屏障。
实验例3：本发明所述目标化合物的抗Aβ1-42聚集作用
采用硫代硫磺素T(ThT)法测定化合物的抗Aβ1-42聚集作用。
具体方法：称取Aβ1-42溶解于六氟异丙醇中，充分溶解后，分装，放置通风橱中过夜，挥发掉六氟异丙醇后冻存。实验之前，取一份样品溶解于DMSO中，再用PBS缓冲液稀释至25μM。化合物用DMSO配置，并用缓冲液稀释，控制最后DMSO含量不高于10％。然后依次向黑色酶标板中加入1μL待测样品和9μLAβ1-42缓冲液，加入完毕后，轻拍使其混合均匀，用盖板膜将96孔板盖好，于室温下静置46-48h。静置结束，加入50mM ThT溶液200μL并于激发波长446nm和吸收波长490nm下测定其荧光吸收。其抑制率(％)计算公式为：抑制率(％)＝1-(IFi/IFo*100)，其中IFi代表抑制剂存在下的荧光吸收；IFo代表无抑制剂存在下的荧光吸收。每个实验重复三次，结果表达为平均值±SD。结果如表6所示
表6目标化合物的抗Aβ聚集作用
a药物浓度在25μM浓度下，对Aβ1-42自身聚集的抑制率。
如表6所示，化合物I-1、I-9、I-10、I-15、I-16表现出了较好的抗Aβ聚集作用，I-2、I-5、I-6、I-7、I-14、I-15、I-16表现出了中等强度的抗Aβ聚集作用，表明本发明所述目标化合物可以一定程度的抗Aβ聚集。
实验例4：目标化合物I-10的神经细胞毒性
采用MTT法测定化合物对神经细胞的毒性，上市药物雷沙吉兰(rasagiline)选做阳性对照。
具体方法：人神经母细胞瘤细胞(SH-SY5Y)培养在含有10％胎牛血清的EMEM和F-12(1:1)混合培养基中，并加入110U/mL青霉素和100μg/mL链霉素作为双抗。待细胞生长满培养瓶约80％后，将细胞以10000个/孔转入96孔板中培养。24h后，换液，加入相应浓度的测试化合物，继续孵育48h。孵育结束后，加入20μL MTT。4h后，移去培养基加入200μL DMSO，溶解生成的甲瓒，并在570nm下测定吸光度计算生存率。结果如图2所示。
由图2可知，对比雷沙吉兰，目标化合物I-10在100和50μM浓度下有一定的神经毒性，但在25、12.5和6.25μM浓度下则较为安全，由于目标化合物I-10对MAO-B的抑制在4nM，因此在有效浓度范围内I-10具有良好的安全性。
Claims (3)
1.具有下述式I-13～I-20所示结构的化合物或其药学上可接受的盐在制备治疗阿尔茨海默病药物中的应用；
2.一种治疗阿尔茨海默病的药物，其特征在于：它含有治疗上有效剂量的下述式I-13～I-20所示结构的化合物或其药学上可接受的盐以及药学上可接受的辅料；
3.根据权利要求2所述的药物，其特征在于：所述药物的剂型为药学上可接受的剂型。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010071179.5A CN111228252B (zh) | 2020-01-21 | 2020-01-21 | 丙炔胺类衍生物在制药中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010071179.5A CN111228252B (zh) | 2020-01-21 | 2020-01-21 | 丙炔胺类衍生物在制药中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111228252A CN111228252A (zh) | 2020-06-05 |
| CN111228252B true CN111228252B (zh) | 2022-11-29 |
Family
ID=70876241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010071179.5A Expired - Fee Related CN111228252B (zh) | 2020-01-21 | 2020-01-21 | 丙炔胺类衍生物在制药中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111228252B (zh) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1031995C (zh) * | 1991-01-02 | 1996-06-12 | 奥韦特有限公司 | N-炔丙基-1-氨基茚满的r-对映体的制法 |
| CN101703501B (zh) * | 2009-09-29 | 2011-07-27 | 浙江工业大学 | 一种炔丙基亚胺类化合物及其在制备mao抑制剂中的应用 |
| JP2017503769A (ja) * | 2013-08-30 | 2017-02-02 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | 選択的ｍａｏ−ｂ阻害剤化合物、その医薬組成物及びその使用 |
| CN109251155A (zh) * | 2017-07-14 | 2019-01-22 | 广东东阳光药业有限公司 | α-氨基酰胺衍生物及其用途 |
-
2020
- 2020-01-21 CN CN202010071179.5A patent/CN111228252B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN111228252A (zh) | 2020-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103923010B (zh) | 11-取代氧化异阿朴菲衍生物及其合成方法和应用 | |
| Wang et al. | Novel multipotent phenylthiazole–tacrine hybrids for the inhibition of cholinesterase activity, β-amyloid aggregation and Ca2+ overload | |
| Cheng et al. | (−)-Meptazinol–melatonin hybrids as novel dual inhibitors of cholinesterases and amyloid-β aggregation with high antioxidant potency for Alzheimer’s therapy | |
| Pistolozzi et al. | Chemical and Pharmacological Studies on Enantiomerically Pure p‐Methoxytacripyrines, Promising... | |
| Xue et al. | Discovery of potent PTP1B inhibitors via structure-based drug design, synthesis and in vitro bioassay of Norathyriol derivatives | |
| CN103923009B (zh) | 8-取代氧化异阿朴菲衍生物及其合成方法和应用 | |
| CN111228252B (zh) | 丙炔胺类衍生物在制药中的应用 | |
| CN103450163B (zh) | 吲唑类化合物、其制备方法及其药物用途 | |
| CN109796471B (zh) | 吲哚酮螺环丙烷螺-噻唑酮或螺-四氢噻唑酮类衍生物及其制备方法和应用 | |
| CN110003160B (zh) | 一种蛇床子素腙类/酰腙类/磺酰腙类衍生物及其制备方法以及应用 | |
| CA2895968C (en) | Crystal form of compound used as mineralocorticoid receptor antagonist and preparation method therefor | |
| CN113831296B (zh) | 1-苯基-3-(4-(嘧啶-5-基氨基)苯基)丙-2-烯-1-酮类化合物及其用途 | |
| WO2022110842A1 (zh) | 左旋氟吡咯酮的晶型a及其制备方法 | |
| CN107737126B (zh) | 香豆素-二硫代氨基甲酸酯衍生物在制药中的应用 | |
| CN103012394B (zh) | 一种罗丹宁衍生物及其制备方法 | |
| CN102218063A (zh) | 盐酸丙哌维林药物的制备方法和产品及其检测方法 | |
| CN111170877B (zh) | 丙炔胺类衍生物及其合成方法 | |
| CN114478318B (zh) | 二腈异佛尔酮衍生物、其制备方法及应用 | |
| CN109456328B (zh) | 11-取代1,6-二氮杂苯并蒽酮衍生物及其合成方法和应用 | |
| CN111333636B (zh) | 噻唑酰胺类衍生物及其在抗肿瘤药物中的应用 | |
| CN109438445B (zh) | 8-取代1,6-二氮杂苯并蒽酮衍生物及其合成方法和应用 | |
| CN113015722B (zh) | 一种低氧诱导因子脯氨酰羟化酶抑制剂晶型 | |
| CN108329282B (zh) | 一种苯基哌嗪类衍生物及其制备方法和应用 | |
| Patowary et al. | In Silico Study, Synthesis, and In Vitro Evaluation of Acetylcholinesterase and Butyrylcholinesterase Inhibitory Activity of Novel N‐Thiazole Substituted Acetamide Coumarin Derivatives | |
| CN119343349A (zh) | 螺环化合物和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20221129 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |